EGFR and non-small cell lung carcinoma: At present, targeted therapies such as tyrosine kinase inhibitors (TKI), antibodies against epidermal growth factor receptor (EGFR), inhibitors for anaplastic lymphoma kinase (ALK), and chemotherapy with platinum-based doublets have been the choice for first line treatment of advanced NSCLC.